28.94
Schlusskurs vom Vortag:
$28.99
Offen:
$28.81
24-Stunden-Volumen:
75,091
Relative Volume:
0.68
Marktkapitalisierung:
$967.98M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-5.4713
EPS:
-5.2894
Netto-Cashflow:
-
1W Leistung:
+9.54%
1M Leistung:
+20.03%
6M Leistung:
+8.47%
1J Leistung:
+0.00%
Spyglass Pharma Inc Stock (SGP) Company Profile
Firmenname
Spyglass Pharma Inc
Sektor
Branche
Telefon
949-284-6904
Adresse
27081 ALISO CREEK ROAD, ALISO VIEJO
Compare SGP vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
SGP
Spyglass Pharma Inc
|
28.94 | 877.34M | 0 | 0 | 0 | -5.2894 |
|
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
|
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spyglass Pharma Inc Stock (SGP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-03-03 | Eingeleitet | Citigroup | Buy |
| 2026-03-03 | Eingeleitet | Jefferies | Buy |
| 2026-03-03 | Eingeleitet | Leerink Partners | Outperform |
| 2026-03-03 | Eingeleitet | Stifel | Buy |
Spyglass Pharma Inc Aktie (SGP) Neueste Nachrichten
SpyGlass (SGP): Finishes 1.91% Lower at $26.71; Technical Setup: the Current Price Sits Inside the Supplied Technical Range in the Available RecordWyckoff Accumulation - vinanet.vn
SpyGlass (SGP) Financial Update: Profit Per Share Falls Below Its Benchmark under the Current Snapshot - vinanet.vn
SpyGlass Pharma, Inc. (NASDAQ: SGP) Share Price, SGP Stock News, SGP Share Price & Updates - Kalkine
SpyGlass Pharma (SGP) Slides 2.4% as Shares Test Mid-Range Support ZoneBlock Trade Flow - vinanet.vn
Spyglass Pharma (SGP) Insider Trading Activity 2026 $SGP - MarketBeat
Spyglass Pharma (NASDAQ:SGP) Upgraded to "Moderate Buy" at Raymond James Financial - MarketBeat
Analysts Offer Insights on NA Companies: Ottobock SE & Co. KGaA (OtherOBCKF), SpyGlass Pharma (Nasdaq: SGP) and Figure Technology Solutions, Inc. Class A (FIGR) - The Globe and Mail
Raymond James Initiates SpyGlass Pharma(SGP.US) With Buy Rating, Announces Target Price $39 - Moomoo
Raymond James initiates SpyGlass Pharma stock coverage with outperform rating - Investing.com
Q3 EPS Estimates for Spyglass Pharma Decreased by Analyst - MarketBeat
SpyGlass Pharma Reports Q2 Financials, Provides Corporate Updates - VisionMonday.com
SpyGlass Pharma Ord shs (Proposed) (SGP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Spyglass Pharma, Inc. (NASDAQ:SGP) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
SpyGlass Pharma 2Q 2026: Net loss $(19.9)M, EPS $(0.59) — 10-Q Summary - TradingView
[10-Q] SpyGlass Pharma, Inc. Quarterly Earnings Report - Stock Titan
SpyGlass Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
SpyGlass Pharma reports $19.9M Q2 net loss, $234.2M cash and investments as of June 30, 2026 - TradingView
SpyGlass Pharma Q2 net loss widens on higher expenses - TradingView
SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - Yahoo Finance
SpyGlass Pharma Insiders Enjoying US$1.1m Appreciation On US$2.16m Investment - webull.com
SpyGlass Pharma (SGP) Rallies 3.08% to $24.41 as Ophthalmic Focus Draws Fresh BuyingLow Vol Factor - dars.gov.et
22,536,164 Common Stock of SpyGlass Pharma, Inc. are subject to a Lock-Up Agreement Ending on 5-AUG-2026. - marketscreener.com
SpyGlass Pharma (SGP) Gains 1.34% as Stock Tests Key Resistance LevelPoint of Control - dars.gov.et
SGP|SpyGlass Pharma Ord shs (Proposed)|Price:20.490|Chg%:-0.390 - TradingKey
Spyglass Pharma (NASDAQ:SGP) Shares Gap UpStill a Buy? - MarketBeat
SpyGlass Pharma, Inc. Revenue Breakdown – NASDAQ:SGP - TradingView
SpyGlass Pharma Q1 2026 Earnings: EPS Misses Estimates as Company Advances PipelineWeak Earnings Momentum - vinanet.vn
SpyGlass Pharma (SGP) Jefferies Global Healthcare Conference 2026 Summary - Quartr
SpyGlass Pharma Holds Steady Near Support as Traders Eye Key LevelsSmart Money Flow Stocks - vinanet.vn
Top Spyglass Pharma (SGP) Competitors 2026 - MarketBeat
SpyGlass Pharma (SGP) Drops 4.77% as Key Support Levels Are TestedFade Trade - dars.gov.et
SpyGlass Pharma (SGP) Dips Nearly 5%, Testing Key Support LevelsInstitutional Flow Picks - vinanet.vn
SGP Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues R&D InvestmentCore Business Growth - vinanet.vn
SpyGlass Pharma (SGP) Rallies 2.67%, Tests Key Resistance LevelRatio Spread Trade - dars.gov.et
SGP Q1 2026 Earnings: EPS Misses Estimates as Revenue Remains AbsentEarnings Miss Alert - dars.gov.et
SpyGlass Pharma Inc. (SGP) Q1 2026 Earnings: Wider-Than-Expected Loss Triggers Double-Digit Selloff - dars.gov.et
SGP Q1 2026 Earnings: EPS Misses Estimates, Stock Edges HigherLong-Term Guidance - dars.gov.et
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 2000 Index - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS:SGP) added to Russell Microcap Value Benchmark Index - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 2000 Value Benchmark - marketscreener.com
SpyGlass Pharma (SGP) Registration Filing Summary - Quartr
SpyGlass Pharma, Inc.(NasdaqGS:SGP) added to Russell Microcap Growth Benchmark Index - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 2000 Growth Benchmark - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 3000E Growth Benchmark - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell Microcap Index - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell Small Cap Completeness Index - marketscreener.com
SGP Forecast — Price Target — Prediction for 2027 - TradingView
Transcript : SpyGlass Pharma, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 10 - marketscreener.com
SpyGlass Pharma, Inc. Actuals & Estimates (NASDAQ:SGP) - TradingView
Price to sales forward of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
Enterprise value to revenue forward of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
Finanzdaten der Spyglass Pharma Inc-Aktie (SGP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Spyglass Pharma Inc-Aktie (SGP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Behbahani Ali | Director |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Florence Anthony A. Jr. | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| BASKETT FOREST | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| New Enterprise Associates 17, | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Yang Rick | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Makhzoumi Mohamad | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| SANDELL SCOTT D | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Chang Carmen | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Walker Paul Edward | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Mathers Edward T | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):